The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).
 
Christina Lynn Roland
Research Funding - Bristol-Myers Squibb
 
Emily Zhi-Yun Keung
No Relationships to Disclose
 
Alexander J. Lazar
Leadership - Archer; Iterion Therapeutics; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb; Deciphera; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Keila E Torres
No Relationships to Disclose
 
Wei-Lien Wang
No Relationships to Disclose
 
Ashleigh Guadagnolo
No Relationships to Disclose
 
Andrew Justin Bishop
No Relationships to Disclose
 
Heather Y. Lin
No Relationships to Disclose
 
Kelly Hunt
Consulting or Advisory Role - Armada Health Care; Merck
Research Funding - Endomagnetics (Inst); Lumicell (Inst); OncoNano Inc (Inst)
 
Barry W. Feig
No Relationships to Disclose
 
Justin E. Bird
No Relationships to Disclose
 
Valerae O. Lewis
No Relationships to Disclose
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)
 
Ravin Ratan
Stock and Other Ownership Interests - Johnson & Johnson (I)
Consulting or Advisory Role - Epizyme
Research Funding - Epizyme; SpringWorks Therapeutics
 
Shreyaskumar Patel
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Daiichi Sankyo; Epizyme; Immune Design; Janssen; Lilly; MaxiVax ; Novartis
Research Funding - Blueprint Medicines (Inst)
 
Jennifer Ann Wargo
Leadership - Microbiome DX
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Dava Oncology; Genentech; Gilead Sciences; GlaxoSmithKline; Illumina; Merck; Novartis; Society for Immunotherapy of Cancer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck; Novartis
Speakers' Bureau - Dava Oncology; Genentech; Illumina; Novartis; PER; Precision Health Economics; Precision Health Economics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; Genentech; GlaxoSmithKline; Illumina; Novartis
 
Neeta Somaiah
Consulting or Advisory Role - Bayer; Bayer; Blueprint Medicines; Deciphera; Immune Design
Research Funding - MedImmune